Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Change in Acquisitions & Divestments (2016 - 2025)

Historic Change in Acquisitions & Divestments for Gyre Therapeutics (GYRE) over the last 14 years, with Q1 2025 value amounting to $11.2 million.

  • Gyre Therapeutics' Change in Acquisitions & Divestments changed N/A to $11.2 million in Q1 2025 from the same period last year, while for Sep 2025 it was $11.2 million, marking a year-over-year change of. This contributed to the annual value of $2.5 million for FY2022, which is 9489.27% down from last year.
  • Gyre Therapeutics' Change in Acquisitions & Divestments amounted to $11.2 million in Q1 2025.
  • In the past 5 years, Gyre Therapeutics' Change in Acquisitions & Divestments registered a high of $27.6 million during Q1 2021, and its lowest value of $2.5 million during Q1 2022.
  • Over the past 3 years, Gyre Therapeutics' median Change in Acquisitions & Divestments value was $9.3 million (recorded in 2021), while the average stood at $10.5 million.
  • Examining YoY changes over the last 5 years, Gyre Therapeutics' Change in Acquisitions & Divestments showed a top increase of 1756.28% in 2021 and a maximum decrease of 9144.04% in 2021.
  • Gyre Therapeutics' Change in Acquisitions & Divestments (Quarter) stood at $2.9 million in 2021, then decreased by 12.63% to $2.5 million in 2022, then surged by 346.88% to $11.2 million in 2025.
  • Its Change in Acquisitions & Divestments stands at $11.2 million for Q1 2025, versus $2.5 million for Q1 2022 and $2.9 million for Q4 2021.